The capital stack
that builds the future.
Project Eden Ghana is structured for institutional capital: four ring-fenced tranches, seven uncorrelated revenue layers and a live model driven by the same digital twin that runs the campus. Move the drivers, price your own ticket, take the term sheet with you.
Four tranches.
One bankable organism.
Every tranche is ring-fenced to a measurable asset and reported through the ESG engine of the Commercial Intelligence Layer.
Development Equity
The founding layer. Funds the physical organism: intake halls, HPP and aseptic trains, the pharma-grade chromatography suite and the digital twin that runs them.
- Instrument
- Ordinary equity · SPV Eden Somanya Ltd
- Minimum ticket
- $250,000
- Tenor
- 7 years
- Equity in tranche
- 46% of SPV
- Target IRR
- 26.4%
- Target MOIC
- 3.1×
- Security
- Direct shareholding in the campus SPV, board seat above $5M
- Use of proceeds
- Campus construction, Zone A–F process lines, iEDEN-OS control room
Drive the drivers.
Watch the organism re-price.
Utilisation, global price index, energy self-supply and carbon price flow through every revenue layer, the cash waterfall and your own ticket economics in real time.
Price your allocation.
Then take the paperwork.
Size a ticket in any tranche, see the modelled distribution schedule, IRR and MOIC, download an indicative term sheet and open a file with the Eden Ghana capital desk.
What we have built.
What could bite.
- Q2 2025Land secured & ESIA cleared
1,200 acres registered, ESIA approved by Ghana EPA.
- Q4 2025Anchor equity closed
$27.3M of Tranche I committed by strategic agro-industrial partners.
- Q3 2026Zone A–C commissioning
Intake, sorting, HPP and aseptic purée lines hot-commissioned.
- Q1 2027GMP pharma suite certified
EU GMP inspection for Bromelain-Ultra™ and Mangiferin-Eden™.
- Q3 20276MW energy island live
Biogas + solar hybrid at 78% self-supply, grid export agreement.
- Q2 2028First licensing royalty
Eden Bio-Film™ licensed to a European packaging manufacturer.
11,000-farmer catchment across four agro-zones, irrigated nucleus block, IQF buffer stock.
Parallel nutraceutical-grade route monetises the same extract while GMP audit completes.
94% of revenue invoiced in USD/EUR, local cost base naturally hedged.
Contracted reefer allocation with two carriers plus air bridge for pharma actives.
Carbon is 4% of Year 5 revenue; the margin ratchet is upside, not covenant.
No buyer exceeds 12% of revenue; 14 offtakes across four corridors.
Commitments in flight.
Every expression of interest opens an auditable file — NDA execution, diligence, allocation and funding, all tracked with the capital desk.
Enter the live data room
NDA-cleared members receive real-time P&L, yield predictions, cold chain telemetry and carbon credit balances streamed directly from iEDEN-OS™, alongside the full diligence library.
Infrastructure economics with consumer-brand margins.
Model the scenario, size the ticket, download a watermarked term sheet and open the permissioned diligence room in the same session.